Computational screening of natural inhibitors against Plasmodium falciparum kinases: Toward novel antimalarial therapies
PLOS One · 2026
DOI: 10.1371/journal.pone.0339317 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Muharib Alruwaili und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, Saudi Arabia. Hauptthemen laut MEDLINE: Plasmodium falciparum, Antimalarials, Cyclic GMP-Dependent Protein Kinases, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
An important worldwide problem is the resistance of Plasmodium falciparum to practically all antimalarial medications. Therefore, new treatment approaches are urgently needed. The development of antimalarial medications frequently involves two important therapeutic targets: casein kinase 2 (CK2) and cGMP-dependent protein kinase (PKG). To identify naturally occurring chemicals that could be used as antimalarial medications to combat multidrug-resistant P. falciparum , we used a multi-targeted in silico strategy in this study. The top 20 compounds, including the reference drug RY-1–65, were selected after pharmacophore-based virtual screening of naturally produced compounds. These compounds were subsequently docked onto both target proteins using Maestro (Schrödinger 2020−3). The best-scoring compounds against PKG and CK2 were Ligand-9 (−7.490 kcal/mol) and Ligand-13 (−11.468 kcal/mol), respectively. These lead compounds may be useful as therapeutic targets based on an assessment of their pharmacological, toxicological, and bioactivity characteristics. Furthermore, Ligand-13’s strong reactivity and stability were demonstrated by density functional theory analysis, and these findings were confirmed by molecular dynamics simulations and binding free energy MMGBSA calculations. These results imply that Ligand-13 may be a promising antimalarial medication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, Saudi Arabia.
- Centre for Immunology and Infection (C2i), Hong Kong Science and Technology Park, Hong Kong, SAR China.
- HKU-Pasteur Research Pole, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR China.
- School of Medicine, Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, United Kingdom.
- Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
ORCID-Profile: Muharib Alruwaili, Jeremy Millis, Muhammad Umer Khan, Hasan Ejaz
Zitieren
APA
Alruwaili, M., Younas, S., Elderdery, A. Y., Alruwaili, I., Millis, J., Khan, M. U., & Ejaz, H. (2026). Computational screening of natural inhibitors against Plasmodium falciparum kinases: Toward novel antimalarial therapies. PLOS One. https://doi.org/10.1371/journal.pone.0339317
Vancouver
Alruwaili M, Younas S, Elderdery AY, Alruwaili I, Millis J, Khan MU, et al. Computational screening of natural inhibitors against Plasmodium falciparum kinases: Toward novel antimalarial therapies. PLOS One. 2026. doi:10.1371/journal.pone.0339317
BibTeX
@article{Alruwaili2026,
author = {Alruwaili, Muharib and Younas, Sonia and Elderdery, Abozer Y and Alruwaili, Intisar and Millis, Jeremy and Khan, Muhammad Umer and Ejaz, Hasan},
title = {Computational screening of natural inhibitors against Plasmodium falciparum kinases: Toward novel antimalarial therapies},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0339317}
}
EUVIMED